** Shares of biotech firm Humacyte HUMA.O down 23.5% premarket to $2.20, over 16-mth low, after overnight follow-on priced

** Durham, North Carolina-based co late Tues sold 25 mln shares at $2 for $50 mln gross raise

** Offering priced at 30.6% discount to last sale

** Co intends to use net offering proceeds to fund commercialization of its implant Symvess for patients with extreme blood vessel injury

** U.S. FDA granted approval of Symvess in Dec

** HUMA has ~122.7 mln shares outstanding for ~$353 mln market cap, and ~89.7 mln shares of public float, per LSEG data

** TD Cowen, Barclays and BTIG jt bookrunners for the offering

** Through Tues, HUMA shares down 43% YTD after ~78% gain in 2024

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))